INT103020

Context Info Confidence 0.56 First Reported 2002 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 22 Total Number 23 Disease Relevance 14.29 Pain Relevance 2.75

cytoskeleton (SGCA) cytoplasm (SGCA)

Anatomy Link Frequency ADF 1 neurons 1 arm 1 pupil 1 upper 1 SGCA (Homo sapiens)

Pain Link Frequency Relevance Heat backache 18 99.52 Morphine 1 98.36 analgesia 1 98.00 Pain 122 88.16 antagonist 21 87.32 Opioid 3 86.88 Analgesic 4 76.08 opiate 1 75.00 opioid receptor 1 68.72 addiction 28 63.60

Disease Link Frequency Relevance Heat Disease 737 100.00 Benign Prostatic Hypertrophy 115 100.00 Prostate Cancer 45 100.00 Pulmonary Disease 33 100.00 Low Back Pain 18 99.52 Dyspnea 94 99.48 Lymphedema 89 99.44 Chronic Disease 90 99.28 Hydrocele 82 98.48 Lifespan 70 98.28

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

The efficacy of the present rehabilitation program early after surgery was demonstrated in terms of recovery of ADL as well as the ROM of the arm on the affected side.

Gene_expression (recovery) of ADL in arm

1) Confidence 0.56 Published 2003 Journal Nurs Health Sci Section Abstract Doc Link 14622379 Disease Relevance 0.55 Pain Relevance 0.33

Those expressed extracellularly and with an average expression level at least three-fold greater in BPH RNA pools than in the prostate cancer RNA pools included: CDH13, CHRNB1, COL4A5, EFEMP2, EMP3, F10 (16-fold), FGF2, FGFBP1 (10-fold), IGF1, IGF2 (18-fold), LIPG, RARB, SGCA, SGCD, TGFB1, TGFB3 (14-fold), TGFBR2 and TIMP2 of the “high in BPH, moderate in prostate cancer” group; SMOC1 (26-fold) in the “high in BPH, low in prostate cancer” group; and SCGB3A1 (15-fold) and SCGB1A1 (14-fold) in the “moderate in BPH, low in prostate cancer” group.

Gene_expression (expressed) of SGCA associated with benign prostatic hypertrophy and prostate cancer

2) Confidence 0.49 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793011 Disease Relevance 2.48 Pain Relevance 0

The variation could be due to differences in prevalence of chronic disease and differential susceptibility to ADL episodes for individuals with lymphoedema and hydrocele.

Gene_expression (episodes) of ADL associated with hydrocele, lymphedema and chronic disease

3) Confidence 0.42 Published 2005 Journal BMC Public Health Section Body Doc Link PMC1156912 Disease Relevance 0.74 Pain Relevance 0

As there are no other diagnostic tools to identify ADL episodes, the present method of symptomatic diagnosis was used.

Gene_expression (episodes) of ADL

4) Confidence 0.42 Published 2005 Journal BMC Public Health Section Body Doc Link PMC1156912 Disease Relevance 0.53 Pain Relevance 0.09

Clinical symptoms associated with ADL episodes

Gene_expression (episodes) of ADL

5) Confidence 0.42 Published 2005 Journal BMC Public Health Section Body Doc Link PMC1156912 Disease Relevance 1.24 Pain Relevance 0.07

s study confirmed peripheral restriction of ADL 8-2698 by its lack of central effect on morphine analgesia and pupil miosis.

Gene_expression (restriction) of ADL in pupil associated with miosis, analgesia and morphine

6) Confidence 0.37 Published 2002 Journal Minerva Anestesiol Section Abstract Doc Link 12024075 Disease Relevance 0.40 Pain Relevance 0.80

The factor mobility was excluded from the ADL groups, as this was assessed separately using data from other questions.

Gene_expression (groups) of ADL

7) Confidence 0.18 Published 2004 Journal BMC Health Serv Res Section Body Doc Link PMC517924 Disease Relevance 0.07 Pain Relevance 0

Consistent with this, patients in our study demonstrated significant decreases in the KOOS ADL and Sport/Rec subscales in the first two weeks after surgery.

Gene_expression (decreases) of ADL

8) Confidence 0.16 Published 2008 Journal Health Qual Life Outcomes Section Body Doc Link PMC2614963 Disease Relevance 0.29 Pain Relevance 0.14

Many ADL involve arm activities, and in COPD, upper extremity activities produce substantial dyspnea.

Gene_expression (produce) of ADL in upper associated with pulmonary disease and dyspnea

9) Confidence 0.09 Published 2008 Journal Journal of Medical Internet Research Section Body Doc Link PMC2483918 Disease Relevance 0.65 Pain Relevance 0

The estimated higher proportion of clinical disease patients with hydrocele (62.5%) compared to lymphedema (37.5%) offsets the greater average disability of lymphedema patients in terms of their ADL frequency, ADL duration, and percentage of work time lost due to disease.

Gene_expression (frequency) of ADL associated with hydrocele, lymphedema and disease

10) Confidence 0.07 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2879371 Disease Relevance 0.90 Pain Relevance 0

The estimated higher proportion of clinical disease patients with hydrocele (62.5%) compared to lymphedema (37.5%) offsets the greater average disability of lymphedema patients in terms of their ADL frequency, ADL duration, and percentage of work time lost due to disease.

Gene_expression (duration) of ADL associated with hydrocele, lymphedema and disease

11) Confidence 0.07 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2879371 Disease Relevance 0.90 Pain Relevance 0

Scores on the ADCS-ADL19 were similar in both groups at baseline, but at 28 weeks, patients in the memantine group had significantly better outcome than patients in the placebo group in both the LOCF (?

Gene_expression (Scores) of ADCS-ADL19

12) Confidence 0.07 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.40 Pain Relevance 0

2.5, p<0.001) and ADCS-ADL19 (?

Gene_expression (2.5) of ADCS-ADL19

13) Confidence 0.07 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.14 Pain Relevance 0

The ADCS-ADL19 did not differ significantly between groups at Week 24 endpoint (?

Gene_expression (The) of ADCS-ADL19

14) Confidence 0.07 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0 Pain Relevance 0.03

2.4, p<0.001) and ADCS-ADL19 (?

Gene_expression (2.4) of ADCS-ADL19

15) Confidence 0.07 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.12 Pain Relevance 0

In most studies, ADL is assessed with the Alzheimer’s Disease Cooperative Study (ADCS) ADL scale.

Gene_expression (assessed) of ADL associated with disease

16) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695219 Disease Relevance 0.88 Pain Relevance 0

Assessment of ADL

Gene_expression (Assessment) of ADL

17) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695219 Disease Relevance 0.83 Pain Relevance 0

Finally, Feldman et al focused on ADL effect of memantine using ‘observed case’ (OC) and ‘mixed model repeated measures’ (MMRM) approaches.32 Three response categories relative to basement on the ADCS-ADL19 were created (improvement >0, ?

Gene_expression (effect) of ADL

18) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695219 Disease Relevance 0.28 Pain Relevance 0

In most studies, ADL is assessed with the Alzheimer’s Disease Cooperative Study (ADCS) ADL scale.

Gene_expression (assessed) of ADL associated with disease

19) Confidence 0.04 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695219 Disease Relevance 0.89 Pain Relevance 0

Hannover ADL score

Gene_expression (Hannover) of ADL

20) Confidence 0.04 Published 2008 Journal Eur Spine J Section Body Doc Link PMC2615123 Disease Relevance 0.64 Pain Relevance 0.64

General Comments

This test has worked.